health
ITM and Lumara Bio Announce Real-World Re-treatment Data and Dosimetry Results from COMPETE for ...
Investigator-led SwissNET registry analysis showed longer real-world progression-free and overall survival for patients re-treated with 177Lu-edotreotide compared to those receiving non-radiopharmaceutical systemic therapyPhase 3 COMPETE trial dosimetry analysis demonstrated favorable tumor-to-kidney absorbed dose ratio with low intra-patient variability
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Dad says he went permanently blind
New York Post
I'm a woman in my 20s and I'm not have the sex I want. I know what's holding me back.
Slate
Millions of cancer cases are linked to 5 common infections: study
New York Post
45-year-old man died after ER sent him home without antibiotics, lawsuit says
OregonLive.com
19 Harmless Symptoms That Are Major Medical Red Flags
BuzzFeed